SCHEMBL336717

SCHEMBL336717

CC(C)C#Cc1ccccc1N

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.52
ALDH1A1 P00352 4/20 0.52
CYP1A2 P05177 3/20 0.52
CYP2C9 P11712 3/20 0.52
CYP2C19 P33261 3/20 0.52
KDM4E B2RXH2 2/20 0.52
MAPT P10636 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MEN1 O00255 1/20 0.52
NPC1 O15118 1/20 0.52
HPGD P15428 1/20 0.52
KMT2A Q03164 1/20 0.52
HSD17B10 Q99714 1/20 0.52
HSP90AA1 P07900 1/20 0.43
NTSR1 P30989 1/20 0.43
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
RET P07949 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20870717 0.83 CYP3A4 (0.48) CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL1922269 0.78 CYP3A4 (0.76) CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL30463848 0.77 CYP1A2 (0.43) CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL29305000 0.75 CA1 (0.46) CYP3A4ALDH1A1MEN1KMT2ATDP1
SCHEMBL449613 0.75 CYP3A4 (0.58) CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL11223381 0.74 KCNH2 (0.48) CYP3A4ALDH1A1CYP1A2TSHR
SCHEMBL20364510 0.74 GRM5 (0.42)
SCHEMBL29031256 0.74 GABRA1 (0.41) CYP3A4CYP1A2HPGDKMT2AL3MBTL1
SCHEMBL14269645 0.72 CYP3A4 (0.60) CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL28392107 0.72 CYP3A4 (0.60) CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097644-B2 Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist ALLERGAN, INC. (US) 2012-01-17 US disclosed
US-8097644-B2 Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist ALLERGAN, INC. (US) 2012-01-17 US disclosed
US-20070232682-A1 Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist ALLERGAN, INC. (US) 2007-10-04 US disclosed
US-20070232682-A1 Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist ALLERGAN, INC. (US) 2007-10-04 US disclosed
WO-2007112322-A2 INDOLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. (US) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232682-A1 Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist S1PR1, S1PR2, S1PR3 CYP3A4 2803/4885ALDH1A1 2262/4885CYP1A2 2468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.